These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32004711)

  • 1. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
    Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
    Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
    Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
    AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
    Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
    Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
    Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics in peritumoral non-enhancing regions: fractional anisotropy and cerebral blood volume improve prediction of local progression and overall survival in patients with glioblastoma.
    Kim JY; Yoon MJ; Park JE; Choi EJ; Lee J; Kim HS
    Neuroradiology; 2019 Nov; 61(11):1261-1272. PubMed ID: 31289886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast MRI with and without contrast agent leakage correction in paediatric brain tumours.
    Novak J; Withey SB; Lateef S; MacPherson L; Pinkey B; Peet AC
    Br J Radiol; 2019 Feb; 92(1094):20170872. PubMed ID: 30358415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
    Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
    Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
    Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.